Tags

Type your tag names separated by a space and hit enter

Iron-chelation therapy with oral chelators in patients with thalassemia major.
Hematology. 2013 Jan; 18(1):50-5.H

Abstract

In thalassemia major (TM), without iron chelation therapy, iron-mediated free radical damage causes liver, endocrine, and myocardial toxicities. Deferoxamine has universally been the standard therapeutic option for iron chelation therapy; however, its usage is troublesome, leading to suboptimal patient compliance. In order to maximize the effectiveness of iron chelation therapy, oral iron chelators deferiprone and deferasirox constitute an important development, offering a potential to improve compliance. Although both oral drugs are effective, they have differences including different pharmacokinetics and side-effect profiles. Our retrospective evaluation of TM patients using oral chelators showed that oral chelators are effective in reducing iron overload regarding ferritin level and partially in cardiac T2* value. However, in our study side effects and discontinuation rates were unexpectedly high and close follow-up of TM patients using oral chelators should be carefully done. The variability in rate of side effects and drug discontinuation in spelenectomized patients using oral chelators suggests that spleen may have a role in pharmacokinetics of these drugs, as well.

Authors+Show Affiliations

Antalya Egitim ve Arastirma Hastanesi Çocuk Hematoloji Bolumu, 07100 Antalya, Turkey. vedat@akdeniz.edu.trNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

23321010

Citation

Uygun, Vedat, and Erdal Kurtoglu. "Iron-chelation Therapy With Oral Chelators in Patients With Thalassemia Major." Hematology (Amsterdam, Netherlands), vol. 18, no. 1, 2013, pp. 50-5.
Uygun V, Kurtoglu E. Iron-chelation therapy with oral chelators in patients with thalassemia major. Hematology. 2013;18(1):50-5.
Uygun, V., & Kurtoglu, E. (2013). Iron-chelation therapy with oral chelators in patients with thalassemia major. Hematology (Amsterdam, Netherlands), 18(1), 50-5. https://doi.org/10.1179/1607845412Y.0000000046
Uygun V, Kurtoglu E. Iron-chelation Therapy With Oral Chelators in Patients With Thalassemia Major. Hematology. 2013;18(1):50-5. PubMed PMID: 23321010.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Iron-chelation therapy with oral chelators in patients with thalassemia major. AU - Uygun,Vedat, AU - Kurtoglu,Erdal, Y1 - 2012/11/19/ PY - 2013/1/17/entrez PY - 2013/1/17/pubmed PY - 2013/12/16/medline SP - 50 EP - 5 JF - Hematology (Amsterdam, Netherlands) JO - Hematology VL - 18 IS - 1 N2 - In thalassemia major (TM), without iron chelation therapy, iron-mediated free radical damage causes liver, endocrine, and myocardial toxicities. Deferoxamine has universally been the standard therapeutic option for iron chelation therapy; however, its usage is troublesome, leading to suboptimal patient compliance. In order to maximize the effectiveness of iron chelation therapy, oral iron chelators deferiprone and deferasirox constitute an important development, offering a potential to improve compliance. Although both oral drugs are effective, they have differences including different pharmacokinetics and side-effect profiles. Our retrospective evaluation of TM patients using oral chelators showed that oral chelators are effective in reducing iron overload regarding ferritin level and partially in cardiac T2* value. However, in our study side effects and discontinuation rates were unexpectedly high and close follow-up of TM patients using oral chelators should be carefully done. The variability in rate of side effects and drug discontinuation in spelenectomized patients using oral chelators suggests that spleen may have a role in pharmacokinetics of these drugs, as well. SN - 1607-8454 UR - https://www.unboundmedicine.com/medline/citation/23321010/Iron_chelation_therapy_with_oral_chelators_in_patients_with_thalassemia_major_ L2 - https://www.tandfonline.com/doi/full/10.1179/1607845412Y.0000000046 DB - PRIME DP - Unbound Medicine ER -